© 2005 Oxford University Press
ARTICLE |
A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2'-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer
Affiliations of authors: Vancouver Cancer Center, BC Cancer Agency, Canada (KNC); Clinical Trials Group, National Cancer Institute of Canada, Kingston, Ontario, Canada (EE, JP, DT); Prostate Center, Vancouver General Hospital, University of British Columbia, Canada (KNC, LF, ECJ, SLG, MEG)
Correspondence to: Kim N. Chi, MD, BC Cancer Agency, Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada (e-mail: kchi{at}bccancer.bc.ca).
Background: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer. Methods: Subjects (n = 25) with localized prostate cancer with high-risk features who were candidates for prostatectomy were treated with OGX-011 by 2-hour intravenous infusion on days 1, 3, and 5 and then weekly from days 8–29 combined with androgen blockade starting on day 1; prostatectomy was performed on days 30–36. Six different doses were tested, from 40 to 640 mg. OGX-011 plasma and prostate tissue concentrations were measured by an enzyme-linked immunosorbent assay method, and the pharmacokinetics of OGX-011 were determined from these data. Prostate cancer tissue, lymph nodes, and serial samples of peripheral blood mononuclear cells were assessed for clusterin expression using quantitative real-time polymerase chain reaction and immunohistochemistry. All statistical tests were two-sided. Results: Only grade 1 and 2 toxicities were observed. The plasma half-life of OGX-011 was approximately 2–3 hours, and the area under the concentration versus time curve and CMAX (peak plasma concentration) increased proportionally with dose (Ptrend<.001). OGX-011 in prostate tissue increased with dose (Ptrend<.001). Dose-dependent decreases in prostate cancer and lymph node clusterin expression were observed by polymerase chain reaction of greater than 90% (Ptrend = .008 and Ptrend<.001, respectively) and by immunohistochemistry (Ptrend<.001 and Ptrend = .01, respectively). Conclusions: OGX-011 is well tolerated and reduces clusterin expression in primary prostate tumors. The optimal biologic dose for OGX-011 at the schedule used is 640 mg.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. R. Graff, B. W. Konicek, J. H. Carter, and E. G. Marcusson Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy Cancer Res., February 1, 2008; 68(3): 631 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Chi, L. L. Siu, H. Hirte, S. J. Hotte, J. Knox, C. Kollmansberger, M. Gleave, E. Guns, J. Powers, W. Walsh, et al. A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer Clin. Cancer Res., February 1, 2008; 14(3): 833 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Moretti, M. M. Marelli, S. Mai, A. Cariboni, M. Scaltriti, S. Bettuzzi, and P. Limonta Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis Cancer Res., November 1, 2007; 67(21): 10325 - 10333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Low, Shuguang Huang, M. Dowless, W. Blosser, T. Vincent, S. Davis, J. Hodson, E. Koller, E. Marcusson, K. Blanchard, et al. High-Content Imaging Analysis of the Knockdown Effects of Validated siRNAs and Antisense Oligonucleotides J Biomol Screen, September 1, 2007; 12(6): 775 - 788. [Abstract] [PDF]
|
|
|
|
 |
|
 K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al. The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor Mol. Pharmacol., September 1, 2007; 72(3): 641 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Graff Targeting the Protein Translation Factor eIF4E for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 153 - 157. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Yu, T.-W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 Drug Metab. Dispos., March 1, 2007; 35(3): 460 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz, M. T. Migawa, T. K. Wyrzykiewicz, G. Hung, B. P. Monia, and a. C. F. Bennett Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals Nucleic Acids Res., January 28, 2007; 35(2): 687 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kamada, A. So, M. Muramaki, P. Rocchi, E. Beraldi, and M. Gleave Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Davis, B. Lollo, S. Freier, and C. Esau Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res., January 1, 2006; 34(8): 2294 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. So, S. Sinnemann, D. Huntsman, L. Fazli, and M. Gleave Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo Mol. Cancer Ther., December 1, 2005; 4(12): 1837 - 1849. [Abstract] [Full Text] [PDF]
|
|